Trolamine Salicylate: A Legacy Sunscreen Ingredient That No Longer Meets Modern Safety Standards

Modern sunscreen regulation increasingly recognises that how an ingredient functions in a formulation matters as much as whether it is formally listed. Trolamine salicylate illustrates how legacy inclusions can persist within regulatory frameworks despite no longer fitting clearly within contemporary scientific or regulatory categories.

Still listed as a permitted sunscreen ingredient in Australia, trolamine salicylate occupies an ambiguous position that reflects historical regulatory settings rather than modern evidence-based evaluation.

A grandfathered listing without a modern public safety foundation

Trolamine salicylate entered regulatory use under early frameworks that did not require the breadth of toxicological, exposure, and quality data now expected for sunscreen actives. No publicly available, contemporary safety assessment exists that evaluates trolamine salicylate using modern Australian exposure models, current toxicological endpoints, or present-day quality standards.

Its continued presence in regulatory listings is therefore best understood as a grandfathered inclusion rather than the outcome of a modern approval process.

An unclear functional role in formulations

Historically, trolamine salicylate was listed as a UV filter, despite providing only weak UVB absorption and no meaningful UVA protection. In contemporary contexts, it is rarely used in modern Australian therapeutic sunscreens. However, its continued listing permits its inclusion in formulations where it may contribute modestly to SPF outcomes or act as an auxiliary salicylate component.

This creates a regulatory blind spot. When a substance contributes, even indirectly, to SPF performance, it effectively participates in the therapeutic function of the product. Yet trolamine salicylate has never been evaluated under modern expectations for substances influencing sunscreen efficacy, whether classified as actives or excipients.

Systemic absorption and pharmacological relevance

Trolamine salicylate is absorbed through the skin to a limited extent and dissociates into salicylic acid and triethanolamine following dermal exposure. At typical concentrations, salicylic acid is often undetectable in serum in healthy adults. However, salicylates are pharmacologically active compounds, and clinical case reports have documented systemic effects including metabolic acidosis, coagulopathy, and bleeding disorders following high-dose or prolonged topical exposure.

These events are uncommon and typically associated with overuse or vulnerable populations such as children, older adults, and individuals taking anticoagulant or antiplatelet medications. Their relevance lies not in suggesting routine risk, but in underscoring that trolamine salicylate is not biologically inert and does not behave like a neutral formulation aid.

Weak UV efficacy and an outdated risk–benefit rationale

From a photoprotective perspective, trolamine salicylate offers limited UVB absorption and lacks the photostability and spectral coverage expected of contemporary sunscreen actives. Its contribution to SPF is modest compared with modern organic and mineral filters.

When this limited efficacy is considered alongside its systemic pharmacological activity and lack of modern safety evaluation, the historical rationale for its inclusion becomes increasingly difficult to defend under current regulatory standards.

Quality and impurity considerations

Modern regulatory frameworks place strong emphasis on quality control, impurity characterisation, and manufacturing consistency. Trolamine salicylate lacks a recognised pharmacopoeial monograph in major compendia such as the USP, BP, or European Pharmacopoeia, and no harmonised specifications exist for impurities.

Triethanolamine-containing compounds are known, under conditions conducive to nitrosation such as contamination with nitrite sources, to present a theoretical risk of nitrosamine formation. While no specific nitrosamine risk assessment has been published for trolamine salicylate, the absence of defined impurity controls represents a gap relative to current expectations for substances used in therapeutic products.

International regulatory divergence

Internationally, regulatory authorities have moved away from permitting trolamine salicylate as a sunscreen active. It is not approved as a UV filter in the European Union, has been classified by the United States Food and Drug Administration as not generally recognised as safe and effective for sunscreen use, and is not permitted in several other major markets.

Australia’s continued listing reflects historical inclusion rather than alignment with current international practice or new evidence supporting its use.

Why reassessment remains relevant

Even if trolamine salicylate is rarely used in modern Australian sunscreens, its continued presence on permissible ingredient lists sets a regulatory precedent. Retaining substances that would not meet modern entry criteria undermines the principle that ingredients influencing sunscreen performance should be supported by current, transparent evidence.

Ambiguity about whether a compound functions as an active ingredient or an excipient does not reduce uncertainty. It increases it.

Moving forward with clarity and modern standards

Revisiting legacy ingredients such as trolamine salicylate is not an indictment of past decisions or a challenge to sunscreen use. It reflects the evolution of scientific understanding and regulatory responsibility.

Effective sun protection is readily achieved using modern, well-characterised UV filters and mineral options such as non nano zinc oxide. Aligning regulatory listings with contemporary safety and quality expectations strengthens public trust and ensures that all substances contributing to sunscreen performance are held to consistent evidence standards.

---

About the Australian Sunscreen Council

The Australian Sunscreen Council (ASC) is dedicated to protecting public health by championing the highest standards in sunscreen safety, testing, use and transparency.

Our mission is to ensure that all sunscreen and related products available to Australians meet or exceed the latest scientific evidence on ultraviolet (UV) protection and human health.

We promote balanced, evidence-based sun safety guidance, recognising that sunscreen is only a small part of the overall picture when it comes to sun safety and health. Our approach is holistic: effective UV protection includes shade, clothing, behaviour, and thoughtful timing of exposure—not sunscreen alone.

The ASC also supports greater public awareness of the documented benefits of moderate sun exposure, including vitamin D synthesis, improved mental wellbeing, and nitric oxide release—a process linked to healthier cardiovascular function and improved blood pressure regulation. We believe Australians deserve clear, science-backed advice that helps them understand how to obtain these benefits safely.

The ASC works collaboratively with government agencies, dermatologists, and public health experts to improve sunscreen standards and to support balanced, science-driven sun safety advice for all Australians.

Learn more at www.australiansunscreencouncil.org